3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Cardiomyopathies, Primary in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Flögel, U; Hohlfeld, T; Jacoby, C; Krügel, U; Meyer-Kirchrath, J; Oros-Peusquens, AM; Pissarek, M; Schramm, N; Vollmar, S | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Cardiomyopathies, Primary
Article | Year |
---|---|
Targeting murine heart and brain: visualisation conditions for multi-pinhole SPECT with (99m)Tc- and (123)I-labelled probes.
Topics: Animals; Benzamides; Brain; Cardiomyopathies; Heart; Humans; Iodine Radioisotopes; Iodobenzenes; Mice; Mice, Transgenic; Myocardium; Oximes; Pyrrolidines; Radiopharmaceuticals; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Swine; Technetium; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2009 |